Dr. Robin Downing spotlights practical OA pain management

Clinician’s Brief is spotlighting osteoarthritis pain management through a sponsored podcast conversation with Dr. Robin Downing, a longtime veterinary pain expert, in an episode focused on practical strategies that go beyond NSAIDs alone. The episode, sponsored by PRN Pharmacal, centers on how clinicians can build more complete pain-control plans and communicate more effectively with pet parents when mobility changes, slowing down, or behavior shifts may reflect pain rather than “just aging.” (cliniciansbrief.com)

That message lands in a veterinary market where osteoarthritis has become a larger clinical and business focus. AAHA’s 2022 Pain Management Guidelines for Dogs and Cats describe chronic musculoskeletal pain, especially OA, as a major area of need and recommend systematic assessment rather than reactive treatment alone. AAHA’s 2023 Senior Care Guidelines add that higher body condition scores and obesity can worsen mobility and inflammatory disease burden in older pets, reinforcing that OA management often starts with the basics: body condition, muscle preservation, mobility screening, and ongoing follow-up. (aaha.org)

The Clinician’s Brief episode itself does not appear to announce a new drug approval or guideline update. Instead, it packages practical clinical advice from Downing for frontline teams trying to manage chronic OA pain more effectively. Clinician’s Brief says the discussion covers implementation of “the most complete and effective strategies for pain control” and communication with pet parents to help identify pain and improve quality of life. That fits Downing’s broader public commentary, where she has argued that pain screening should be part of every physical exam and that multimodal pain management should be standard thinking, not a last resort. (cliniciansbrief.com)

The broader treatment backdrop has changed meaningfully in the past few years. In May 2023, the FDA approved Librela (bedinvetmab injection) as the first monoclonal antibody approved for use in dogs, indicated for control of pain associated with osteoarthritis. The agency said effectiveness was demonstrated in U.S. and EU field studies using the Canine Brief Pain Inventory, with benefit established when at least two monthly doses were given 28 days apart. The label also underscores that the drug is prescription-only and requires veterinary diagnosis, administration, and monitoring. (fda.gov)

Post-approval evidence is also expanding. A March 24, 2025, Frontiers in Veterinary Science study comparing bedinvetmab with meloxicam in 101 client-owned dogs found both treatments significantly reduced Canine Orthopaedic Index scores from baseline, with no statistically significant efficacy difference between groups. The authors reported fewer adverse events in the bedinvetmab arm than in the meloxicam arm, and more dogs in the bedinvetmab group completed the study. Zoetis highlighted those findings in a same-day press release, framing them as support for Librela as an alternative to NSAID therapy in appropriate cases. (frontiersin.org)

Expert commentary around OA care remains consistent on one point: no single intervention solves the whole problem. In Veterinary Practice News, Downing said pain screening should be routine throughout an animal’s life, and she linked untreated pain not only to mobility issues but also to quality-of-life and even behavior changes. For clinicians, that supports a workflow approach in which technicians, veterinarians, and pet parents all contribute to earlier recognition of OA pain through history-taking, palpation, questionnaires, and repeat assessment over time. (veterinarypracticenews.com)

Why it matters: For veterinary professionals, this story is a reminder that OA care is shifting from episodic symptom control to chronic-disease management. The practical takeaway from the Downing podcast, combined with AAHA guidance and newer therapeutic data, is that clinics may need more standardized OA protocols: routine pain screening at wellness visits, weight and muscle-condition tracking, clearer pet parent education, and a tiered treatment framework that can include NSAIDs, adjunct analgesics, rehab, diet, supplements, environmental changes, and biologics when appropriate. That can improve patient outcomes, but it also requires careful case selection, monitoring, and expectation-setting, especially as newer therapies generate both enthusiasm and ongoing scrutiny through post-market surveillance. (cliniciansbrief.com)

What to watch: The next phase is likely to center on protocolization and evidence refinement: more comparative data between OA therapies, more real-world safety reporting, and more emphasis on how practices can operationalize multimodal pain care without losing sight of cost, monitoring burden, and pet parent adherence. (frontiersin.org)